GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmocann Global Ltd (XTAE:PMCN-M) » Definitions » Cyclically Adjusted Revenue per Share

Pharmocann Global (XTAE:PMCN-M) Cyclically Adjusted Revenue per Share : ₪152.89 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Pharmocann Global Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pharmocann Global's adjusted revenue per share data for the fiscal year that ended in Dec. 2023 was ₪7.324. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₪152.89 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Pharmocann Global's average Cyclically Adjusted Revenue Growth Rate was -35.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-24), Pharmocann Global's current stock price is ₪ 2.573. Pharmocann Global's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec. 2023 was ₪152.89. Pharmocann Global's Cyclically Adjusted PS Ratio of today is 0.02.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Pharmocann Global was 0.24. The lowest was 0.01. And the median was 0.03.


Pharmocann Global Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Pharmocann Global's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmocann Global Cyclically Adjusted Revenue per Share Chart

Pharmocann Global Annual Data
Trend Dec09 Dec10 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 299.18 236.53 152.89

Pharmocann Global Quarterly Data
Dec17 Jun18 Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 236.53 - 152.89

Competitive Comparison of Pharmocann Global's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmocann Global's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmocann Global's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmocann Global's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pharmocann Global's Cyclically Adjusted PS Ratio falls into.



Pharmocann Global Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pharmocann Global's adjusted Revenue per Share data for the fiscal year that ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=7.324/129.4194*129.4194
=7.324

Current CPI (Dec. 2023) = 129.4194.

Pharmocann Global Annual Data

Revenue per Share CPI Adj_RevenuePerShare
200912 420.100 91.111 596.733
201012 495.512 92.474 693.480
201612 16.530 101.863 21.002
201712 2.526 104.011 3.143
201812 32.187 105.998 39.299
201912 36.761 108.420 43.881
202012 42.253 109.897 49.759
202112 43.097 117.630 47.417
202212 25.952 125.222 26.822
202312 7.324 129.419 7.324

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Pharmocann Global  (XTAE:PMCN-M) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pharmocann Global's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.573/152.89
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Pharmocann Global was 0.24. The lowest was 0.01. And the median was 0.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pharmocann Global Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Pharmocann Global's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmocann Global (XTAE:PMCN-M) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Ramat Yishai, PO Box 305, Kiryat Tivon, ISR, 3601201
Pharmocann Global Ltd is an Israel-based company engaged in producing medical-related cannabis products which include oil, ointments, tablets, inhalers, rectal and vaginal suppositories, and pre-rolled cigarettes of various types of THC/CBD strains.

Pharmocann Global (XTAE:PMCN-M) Headlines

No Headlines